MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · IEX Real-Time Price · USD
50.21
+0.13 (0.26%)
At close: Mar 27, 2024, 4:00 PM
50.00
-0.21 (-0.42%)
Pre-market: Mar 28, 2024, 7:15 AM EDT

MLTX Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020
Cash & Equivalents
451.1739.518.041.34
Short-Term Investments
59.8432.6100
Cash & Cash Equivalents
511.0172.118.041.34
Cash Growth
608.60%797.08%501.74%-
Receivables
1.060.220.150
Other Current Assets
2.14.181.450.28
Total Current Assets
514.1776.519.641.62
Property, Plant & Equipment
3.950.330.050
Long-Term Investments
000115.01
Other Long-Term Assets
8.42000
Total Long-Term Assets
12.370.330.05115.01
Total Assets
526.5476.849.68116.63
Accounts Payable
1.840.251.570
Current Debt
1.20.15150.06
Other Current Liabilities
6.937.264.520.07
Total Current Liabilities
9.977.6721.090.13
Long-Term Debt
2.50.1300
Other Long-Term Liabilities
0.580.280.244.03
Total Long-Term Liabilities
3.080.410.244.03
Total Liabilities
13.058.0821.334.15
Total Debt
3.70.28150.06
Debt Growth
1208.61%-98.12%25734.01%-
Retained Earnings
-116.66-80.65-53.64-2.52
Comprehensive Income
2.360.35-0.170
Shareholders' Equity
495.6848.9-11.65-2.52
Net Cash / Debt
507.3171.83-6.961.28
Net Cash / Debt Growth
606.24%---
Net Cash Per Share
10.332.45-0.030.14
Working Capital
504.268.85-11.451.49
Book Value Per Share
10.091.67-0.05-0.28
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).